Wall Street Zen Downgrades Gilead Sciences (NASDAQ:GILD) to Hold

Gilead Sciences (NASDAQ:GILD) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Saturday.

GILD has been the subject of a number of other research reports. Barclays reduced their price objective on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 29th. Rothschild & Co Redburn dropped their target price on Gilead Sciences from $170.00 to $167.00 in a research report on Monday, May 11th. Truist Financial cut their target price on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating for the company in a research note on Tuesday, July 7th. Leerink Partners cut Gilead Sciences from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $146.00 to $127.00 in a report on Tuesday, July 21st. Finally, Weiss Ratings downgraded Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, May 28th. Twenty-five analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $157.93.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $130.21 on Friday. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77. The firm has a market cap of $161.66 billion, a price-to-earnings ratio of 17.74 and a beta of 0.32. The firm’s fifty day moving average price is $129.61 and its 200 day moving average price is $135.96. Gilead Sciences has a 1-year low of $108.46 and a 1-year high of $157.29.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The business had revenue of $6.96 billion for the quarter, compared to the consensus estimate of $6.91 billion. During the same quarter in the previous year, the firm earned $1.81 earnings per share. The business’s quarterly revenue was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, sell-side analysts expect that Gilead Sciences will post -0.78 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $125.40, for a total transaction of $376,200.00. Following the completion of the sale, the chief financial officer directly owned 171,646 shares in the company, valued at approximately $21,524,408.40. This trade represents a 1.72% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $131.46, for a total value of $1,971,900.00. Following the sale, the chief executive officer directly owned 617,567 shares in the company, valued at $81,185,357.82. This trade represents a 2.37% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 67,000 shares of company stock worth $8,687,140. 0.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Gilead Sciences

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Brighton Jones LLC boosted its position in shares of Gilead Sciences by 20.6% in the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after buying an additional 2,450 shares in the last quarter. Bison Wealth LLC purchased a new position in Gilead Sciences during the 4th quarter valued at about $215,000. Sivia Capital Partners LLC increased its holdings in Gilead Sciences by 16.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock valued at $464,000 after acquiring an additional 602 shares in the last quarter. Ieq Capital LLC raised its position in Gilead Sciences by 12.0% during the second quarter. Ieq Capital LLC now owns 118,695 shares of the biopharmaceutical company’s stock worth $13,160,000 after acquiring an additional 12,705 shares during the last quarter. Finally, Diversify Advisory Services LLC raised its position in Gilead Sciences by 18.6% during the second quarter. Diversify Advisory Services LLC now owns 4,296 shares of the biopharmaceutical company’s stock worth $516,000 after acquiring an additional 674 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: European regulators issued a positive opinion supporting expanded use of Gilead’s Trodelvy with Keytruda for certain patients with advanced triple-negative breast cancer. The potential label expansion could broaden Trodelvy’s commercial opportunity and strengthen Gilead’s oncology pipeline. Gilead Sciences Following Trodelvy Progress and a Fair Value Debate
• Positive Sentiment: Several analyses remain favorable on GILD. One investment article argues that investors should “buy the distortion” ahead of second-quarter results, while another says the stock still appears inexpensive after delivering roughly 130% total return over five years. Gilead: Buy the Distortion Before Q2 Clears It Up Gilead Stock Stays Cheap on Its Five-Year Run
• Neutral Sentiment: Investor attention is focused on Gilead’s second-quarter 2026 results. Preview articles highlight Wall Street expectations for revenue, earnings and operating metrics, but they do not provide a confirmed earnings surprise. Wall Street Projections for Gilead’s Q2 Metrics
• Positive Sentiment: Analyst coverage remains broadly supportive, with reports noting Gilead’s market outperformance and bullish views on its prospects. However, heightened investor attention alone is not a fundamental catalyst. Do Wall Street Analysts Like Gilead Sciences Stock?
• Negative Sentiment: Erste Group Bank reduced its fiscal 2027 earnings-per-share estimate for Gilead, raising concerns about the company’s future earnings growth. Erste Group Bank Cuts Gilead FY2027 EPS Estimate
• Negative Sentiment: Barclays lowered its Gilead price target to $145. Although the revised target remains above the stock’s referenced trading level, the reduction signals more limited near-term upside and is likely weighing on sentiment. Barclays Lowers Gilead Price Target

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.